Roche's high-dose Ocrevus fails primary endpoint in MS trial

By Yahoo! Finance   |   1 month ago
Roche's high-dose Ocrevus fails primary endpoint in MS trial

Roche's Phase III trial on higher IV Ocrevus doses for relapsing MS did not meet its primary goal but showed similar disability progression rates to approved doses. Despite missing the endpoint, Ocrevus demonstrated clinically meaningful outcomes.

Read More

Did you find this insightful?